Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


EXSCEL evaluated the cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes.


Randomised, placebo-controlled global clinical trial performed in people with type 2 diabetes diabetes, with or without previous cardiovascular disease. In total, 14,752 patients were enrolled between 18th June 2010 and 16th September 2015. EXSCEL was coordinated jointly by the DTU and the Duke Clinical Research Institute (DCRI) and conducted in 687 sites from 35 countries.


The results of EXSCEL were reported at the 2017 meeting of the EASD. It met its primary safety endpoint of non-inferiority for the primary composite cardiovascular endpoint (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke). The corresponding efficacy endpoint analysed for superiority did not reach statistical significance, although a pre-specified analysis suggested all-cause mortality was lower with exenatide compared to placebo. The primary results paper is available here.

Manuscript proposals

The EXSCEL Publications Committee are happy to review proposals for potential new manuscripts. Proposals should be submitted on an EXSCEL Trial Topic Request Form emailed to

Joint chairs

Adrian Hernandez (Previously Robert Califf)
Rury Holman


Amylin Pharmaceuticals, a wholly owned subsidiary of AstraZeneca



Reference numbers

EudraCT 2010-021069-63


EXSCEL Conference Abstracts